This supplier has worked with different contracting methods. The distribution of contracts by method shows the diversity of competitiveness with the public sector.
| Method | # Contracts |
|---|---|
| open | 8 |
| direct | 5 |
| selective | 1 |
Want to know more about Roche? Create and verify your free account to access full information.Create your free account
🏢Roche
What do we know about this supplier?
Roche appears in the public procurement registry of Belgium. Public procurement is the process by which the State acquires goods and services using public funds; its publication is mandatory in most countries to ensure transparency and allow citizens to oversee public spending. This registry documents the individuals and companies that are part of that system. The data in this profile comes from official government sources, accessible through Sociedad.info, a public procurement transparency platform.
Has participated in 14 contracts for a total amount of EUR 53,941,889
Organization typenot reported NITnot reported CountryBelgium Regionnot reported
Reports coming soon
Full reports for this country will be available soon. Leave your email and we will notify you when they are ready.
Contracts
This company has participated in 14 public contracts for a total amount of EUR 53,941,889, demonstrating its ability to work with the public sector.
Public contracts represent an important source of income for companies in Belgium and contribute to the country's economic development.
# Contracts
| Description | Entity | Amount | Award date |
|---|---|---|---|
| 🇧🇪 Specialites pharmaceutiques a base d'erythropoietine (EPO) a courte duree action et d'erythropoietine (EPO) a longue duree d'action remboursees dans le traitement d'une anemie associee a une insuffisance renale. | Association iris-Achats | EUR 528,434 | 2023-03-10 |
| 🇧🇪 Specialite pharmaceutique a base de rituximab pour l'administration sous-cutanee | Association iris-Achats | EUR 1,197,951 | 2022-11-14 |
| 🇧🇪 Raamovereenkomst voor het leveren van rituximab en trastuzumab. | Universitair Ziekenhuis Gent | EUR 7,846,799 | 2017-12-02 |
| 🇧🇪 Fourniture de Medicaments TRASTUZUMAB (Herceptin) et RITUXIMAB (Mabthera). | CHU Tivoli | EUR 1,784,833 | 2017-10-12 |
| 🇧🇪 Trastuzumab-Rituximab | Jan Yperman Ziekenhuis | EUR 5,479,131 | 2020-09-18 |
Contracts by method
Main buyers
Main buyers are the entities that have contracted this supplier the most.
| Entidad | No. Contracts | Total amount |
|---|---|---|
| 🇧🇪 Universitair Ziekenhuis Gent | 4 | EUR 22,596,349 |
| 🇧🇪 Association iris-Achats | 2 | EUR 1,726,386 |
| 🇧🇪 CHU Tivoli | 2 | EUR 3,569,665 |
| 🇧🇪 AZ Delta vzw | 1 | EUR 5,479,131 |
| 🇧🇪 AZ Jan Palfijn Gent | 1 | EUR 5,623,998 |
Additional information
Constitution datenot reported
Last update date2020-05-18
Data sources
Sociedad.info publishes data from official sources, in compliance with public information access laws. Public access to this data is a civic right that helps hold government accountable. This data, including names and identifiers, is already public in the official source. Read our privacy policy.
Published byOpentender.eu
OpenTender obtains information from the procurement portal of the European Union.
This record last updated2020-05-18